Amundi Acquires 38,922 Shares of AtriCure, Inc. $ATRC

Key Points

• Amundi increased its AtriCure stake by 17.2% in the second quarter, adding 38,922 shares and bringing its holdings to 264,854 shares worth approximately $7.4 million. Institutional investors collectively own 99.11% of the company.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding analysts’ revenue expectations. The stock opened at $54.54, near its 12-month high of $55.72, after rising 3.0%.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $52, although insiders have sold 65,036 shares worth approximately $2.76 million over the past 90 days.

Amundi boosted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 17.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,854 shares of the medical device company's stock after purchasing an additional 38,922 shares during the period. Amundi owned about 0.52% of AtriCure worth $7,411,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. HighTower Advisors LLC purchased a new position in shares of AtriCure during the second quarter valued at about $238,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of AtriCure in the 2nd quarter worth about $481,000. California State Teachers Retirement System grew its position in AtriCure by 2,627.3% during the 2nd quarter. California State Teachers Retirement System now owns 1,634,927 shares of the medical device company's stock valued at $45,745,000 after purchasing an additional 1,574,980 shares during the last quarter. Three Seasons Wealth LLC purchased a new stake in AtriCure during the 2nd quarter valued at about $200,000. Finally, Grandeur Peak Global Advisors LLC increased its stake in AtriCure by 53.8% during the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 587,399 shares of the medical device company's stock valued at $16,435,000 after purchasing an additional 205,497 shares in the last quarter. Institutional investors own 99.11% of the company's stock.

AtriCure Stock Up 3.0%

ATRC opened at $54.54 on Friday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 259.73 and a beta of 1.26. The firm has a 50 day moving average price of $42.41 and a 200-day moving average price of $33.55. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $55.72. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts' expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the subject of several recent analyst reports. Needham & Company LLC lifted their target price on shares of AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings raised shares of AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 19th. Piper Sandler boosted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. Finally, Zacks Research cut AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $52.00.

Insider Activity at AtriCure

In other AtriCure news, insider Justin Noznesky sold 6,182 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the transaction, the insider owned 100,219 shares of the company's stock, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen Prange sold 3,564 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director directly owned 22,809 shares in the company, valued at $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,036 shares of company stock valued at $2,758,687 in the last 90 days. 4.00% of the stock is owned by company insiders.

AtriCure Profile

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.